Saturday, July 12, 2025

Latest

Company Overview:

FSD Pharma is focused on the development of the highest quality indoor grown, pharmaceutical grade cannabis and on the research and development of novel cannabinoid-based treatments for several central nervous system disorders, including chronic pain, fibromyalgia and irritable bowel syndrome. The Company has 25,000 square feet available for production at its Ontario facility.

FSD Pharma’s facilities sit on 70 acres of land with 40 acres primed for development and an expansion capability of up to 3,896,000 square feet.

FSD Pharma’s wholly-owned subsidiary, FV Pharma, is a licensed producer under the Cannabis Act and Regulations, having received its cultivation license on October 13, 2017. FV Pharma’s vision is to transform its current headquarters in a Kraft plant in Cobourg, Ontario into the largest hydroponic indoor grow facility in the world. FV Pharma intends to cover all aspects of this exciting new industry, including cultivation, legal, processing, manufacturing, extracts and research and development.

[stock_market_chart symbol=”HUGE.CN” range=”1y” settings='{“primaryChartType”:”smoothedLine”,”width”:”100%”,”height”:”350px”,”marginTop”:0,”marginBottom”:0,”marginLeft”:10,”marginRight”:10,”primaryPanelTitle”:”Price”,”secondaryPanelTitle”:”Volume”,”fontSize”:13,”color”:”#383838″,”primaryLineColor”:”#000″,”primaryLineColorAlpha”:0.15,”secondaryLineColor”:”#000″,”secondaryLineColorAlpha”:0.15,”backgroundColor”:”#fff”,”gridColor”:”#e0e0e0″,”gridAlpha”:0.8,”cursorColor”:”#ba0000″,”cursorAlpha”:0.8,”scrollbarBackgroundColor”:”#fff”,”scrollbarSelectedBackgroundColor”:”#000″,”scrollbarGraphFillColor”:”#000″,”scrollbarSelectedGraphFillColor”:”#000″,”primaryLineThickness”:0,”secondaryLineThickness”:0,”gridThickness”:0,”precision”:2,”thousandsSeparator”:”,”,”decimalSeparator”:”.”,”usePrefixes”:false,”mouseWheelZoomEnabled”:false,”cursorEnabled”:false,”exportEnabled”:false,”scrollbarEnabled”:false,”legendEnabled”:false,”periods”:”1W,1M,6M,YTD,1Y,ALL”,”defaultPeriod”:”1y”}’]

Key Share Information:

Current Share Price$2.24
Market Capitalization (in Millions)$3,110.12
Last Quarter (Share Data)3/31/2019
Shares Outstanding (in Millions)1,388.45
Options (in Millions)94.68
Warrants (in Millions)109.79
Fully Diluted (in Millions)1,592.92
Enterprise Value (in MIllions)$3,094.52
TTM Revenue$0.15
TTM Growth Margin %0.00%
TTM Operating Expenses$42.92
TTM OCF-$4.18
P/S TTM20,669.67
P/S (Last Quarter Run Rate)42,028.71

Key Balance Sheet Information (in Millions $CAD):

CYQ4'16CYQ1'17CYQ2'17CYQ3'17CYQ4'17CYQ1'18CYQ2'18CYQ3'18CYQ4'18CYQ1'19
Cash$0.01$0.03$0.02$0.02$0.01$2.20$31.70$33.79$21.13$17.11
Biological Assets$0.15$0.25
Inventory$0.00$0.14
Total Assets$0.01$0.03$0.02$0.02$0.01$2.24$52.80$66.58$52.78$51.00
Net Tangible Assets$0.01$0.03$0.02$0.02$0.01$2.24$52.80$66.58$52.78$51.00
Intangibles/Goodwill
Total Liabilities$0.08$0.11$0.11$0.11$0.11$0.04$0.31$0.29$1.74$1.50

Key Operating Items (Quarterly in Millions $CAD):

CYQ4'16CYQ1'17CYQ2'17CYQ3'17CYQ4'17CYQ1'18CYQ2'18CYQ3'18CYQ4'18CYQ1'19
Revenue$0.03$0.01$0.09$0.02
Change in Fair Value of Biologial Assets
Gross Margin
Marketing and Sales
Investor Relations$0.000.912.80$1.07
Total Operating Expenses$0.00$0.01$0.00$0.02$0.01$0.05$3.463.0332.86$3.56
Operating Cash Flow (Quarterly)-$0.01-$0.01$0.00-$0.06-$19.014.75-4.17$14.24
Investing Cash Flow (Quarterly)$0.00$0.00$0.00$0.00-$4.44-4.80-0.75$9.51
Financing Cash Flow (Quarterly)$0.04$0.00$0.00$2.25$48.232.13-7.74-$44.17

Listing Statement

Video Articles

Mergers Set the Stage for Uranium’s Growth Cycle | Forum-Baselode Merger

The Goal is Gold Production as Soon as Possible! | Gordon Robb – ESGOLD Corp.

Snowline Gold: The Multi Billion Dollar Valley PEA

Recommended

First Majestic Produces 7.9 Silver Equivalent Ounces In Q2, Lifts Production Guidance

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill